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INTRODUCTION 
 
 
The central nervous system [CNS] is made up of the brain and the spinal 
cord. Cells within the CNS normally grow in an orderly and controlled way. If for 
some reason this disorder is disrupted the cells continue to divide and form a lump 
of tumor. 
 
 Primary brain tumors continue to be among the top ten causes of cancer 
related deaths in the world, despite comparatively low incidence to other  tumors. 
Approximately 14/1,00,000 people are diagnosed with primary brain tumors each 
year and 7/1,00,000 are diagnosed with primary malignant brain tumors. About 
half to three quarters are primary tumors, rest are metastatic. 
 
 Tumors of CNS account of 20% of all cancers of childhood. The incidence 
of brain tumors is 2-5 new cases per 1,00,000 per year.  70% of childhood tumors 
arise in posterior fossa, a comparable number of tumors in adults arise within 
cerebral hemispheres above the tentorium.  
 
 CNS brain tumors is about equal in males and females – 51% for females 
and 49% for males (CBTRUS STUDY). The incidence of malignant CNS tumors 
is greater in males i.e. 7.2/1,00,000. Brain tumor incidence tends to be higher in 
countries with more developed medical care. 
 
Research into the causes of brain tumors is mired by many factors, 
including the relative rarity of the disease and rapid death of patients with 
aggressive subtypes. Investigators have initiated studies of genetic polymorphisms 
that when coupled with certain environmental exposures may lead to brain tumors. 
The possible risk of developing brain cancer from exposure to electromagnetic 
fields through power lines has been investigated. To date, studies do not support 
any such relationship. Another area of popular concern is the possible association 
between head trauma and brain tumor development.  
 
 Central Nervous System tumors have unique characteristics that set them 
apart from neoplastic processes elsewhere in the body. 
 
1. Distinction between benign and malignant neoplasm is less evident in 
CNS than in other organs.  
2. The ability to resect infiltrating glial neoplasms surgically without 
compromising neurologic function is limited 
3. Anatomic site of neoplasm can have lethal consequence irrespective of 
histologic classification. 
4. Pattern of spread of primary CNS neoplasms differ from that of other 
tumors, even the most highly malignant gliomas rarely metastasise 
outside the CNS. 
Glial tumors are the most common primary brain tumors. They are derived 
from astrocytes, oligodendroglial cells and ependyma. Metastatic tumors are by far 
the commonest group of malignancies encountered within nervous system. 
Bronchus, breast and bowel are the most common primary sites but metastases can 
develop from almost anywhere. 
 
Recently there has been conjecture that primary brain tumor incidence is 
increasing. Analysis of the speculation is complicated by diagnostic discrepancies 
and ascertainment bias in registry data. However after extensive review this 
apparent rise is most likely caused by factors such as better diagnostic procedures, 
improved access to medical care and enhanced care for the elderly – all leading to 
greater detection rather than an actual increase in incidence. 
 
Sometimes CNS tumors are very difficult to diagnose under light 
microscopic examination. Immunohistochemical stains play an immense role in 
differentiating these tumors. 
 
In this prosepective study of CNS tumors, incidence with respect to age, 
sex, site and histomorphological features of various tumors are studied with an 
immunohistochemical correlation for some tumors where light microscopic 
examination was difficult. 
 
The recent literature regarding CNS tumors are also reviewed and 
correlated. 
 
REVIEW OF LITERATURE 
 
 Tumors of the central nervous system are a heterogeneous group of 
neoplasms exhibiting a variety of histological features and cytological 
characteristics. Oncogenetically only cells with proliferative capacity in the CNS 
can produce tumors. 
 
 About 60% of primary intracranial neoplasms are gliomas. 20% are 
Meningiomas and the remaining 20% are shared by other tumors. Paediatric CNS 
neoplasms tend to be infratentorial whereas in adults they are mainly 
supratentorial. 
 
Classification and Grading of CNS tumors 
 Baily and Cushing (1926) were pioneers in the histological typing of glial 
tumors. The evaluation of the tumor tissue focused on the resemblance of adult 
glioma cells with cells at various stages of embryogenetic differentiation. 
Kernohan and Sayre (1952) favored a more simplified classification system, which 
subdivided gliomas into astrocytomas, Oligodendrogliomas and ependymomas on 
the basis of cell differentiation. 
 
 Astrocytic tumors comprise a number of cytological and histological 
varieties (Vandenberg 1992, Kleihues et al. 1993a). One fundamental subdivision 
has been made between diffuse astrocytomas, Pilocytic astrocytomas, Pleomorphic 
xanthoastrocytomas and subependymal giant cell astrocytomas (Kleihues et al. 
1993b). The latter three tumors generally represent a more circumscribed growth 
and favorable prognosis. Diffuse astrocytomas show a growth pattern that 
infiltrates the surrounding tissue. The tumor entity has been termed as the 
diffusely infiltrating astrocytomas. They are the most common of the astrocytic 
lesions and encompass three histological variants: the fibrillary type, the 
protoplasmic type and the gemistocytic type. The fibrillary type is the most typical 
variant. Gemistocytic differentiation, also as a composition, has been associated 
with a relatively rapid tumor progression, whereas protoplasmic astrocytomas 
have been shown to represent a more benign tumor behaviour (Watanable et al. 
1997 prayson and Estes 1996). 
 
Grading of CNS tumors 
 Numerous grading systems have been defined for astrocytomas, most use 
the 3 or 4 tier grading system. Currently employed grading systems are WHO 
grading system and the St.Anne Mayo.Grading system. Histological criteria taken 
into consideration are nuclear atypia, mitosis, micro vascular proliferation and / or 
necrosis. 
Thus astrocytoma with none of the above histological features is graded as grade I 
Nuclear atypia  - grade II 
Nuclear atypia + Mitosis - grade III 
Nuclear atypia + Mitosis + Micro vascular proliferation and/or Necrosis-grade-IV 
 WHO uses Roman numericals, whilst St. Anne Mayo uses Arabic 
numericals the only difference is that in WHO systems, tumors such as pilocytic 
astrocytoma, subependymal giant cell astrocytoma are accepted as grade 1 tumors. 
Currently the malignancy scale of  WHO classification and the St. Anne Mayo 
grading system have proved to be both highly reproducible and predictive of 
patient survival. 
 
 Patient’s survival also depends on a variety of clinical parameters including 
patient’s age, clinical condition, tumor location and treatment e.g. Extent of 
surgical resection, postoperative radio and/or Chemotherapy. 
 
Despite these variables, typical ranges of survival are more than 5 years for 
low grade diffuse astrocytoma, 2-5 years for anaplastic astrocytoma and less than 
1 year for Glioblastoma. The WHO grading system is applicable to all other CNS 
neoplasms. Among the other neuroepithelial tumors Oligodendrogliomas are 
graded as II & III. All primitive Neuroectodermal Tumors and primary CNS germ 
cell tumors are graded as IV, but unlike glioblastoma, they have a better mean 
survival time since most are radio or chemo sensitive neoplasms. 
 
Comparison of the World Health Organization  (WHO) and St.Anne/Mayo 
grading system of astrocytomas. 
 
WHO 
Grade 
WHO 
designation 
St. Anne / Mayo 
Designation Histological criteria 
I Pilocytic astrocytoma - - 
II Diffuse Astrocytoma Astrocytoma grade II 
One criterion, usually nuclear 
atypia 
III Anaplastic Astrocytoma Astrocytoma grade III 
Two criteria, usually nuclear 
atypia and mitotic activity 
IV Gliblastoma Multiforme Astrocytoma grade IV 
Three criteria: nuclear atypia, 
mitosis,endothelial proliferation 
and/or necrosis 
     
 Diagnosis of CNS tumors is assisted by the use of specialised histochemical 
stains for glial cells, neurons and other CNS elements. These techniques however, 
have been largely replaced by the more sensitive and specific 
immunohistochemical methods. For glia the cajal gold chloride sublimate method 
has been replaced with the glial fibrillary acidic protein (GFAP) immunostaining 
and the Bielscowsky silver impregnation for neuronal elements by 
immunostaining using antibody to synaptophysin, neurofilament protein and 
microtubule associated protein. Use of the phosphotungstic acid hematoxylin 
(PTAH) technique for glial processes has been largely retained. For vascular 
tumors special stains like Masson’s trichrome, Verhoffs and reticulin are used.  
The staining for the glial fibrillary intermediate filament is present in normal, 
reactive and neoplastic astrocytes (paetau 1989, burger et al, 1991). GFAP 
expression in astrocytoma has been shown to decrease along with the 
differentiation process (Schiffer et al, 1986). Other routinely used 
immunohistochemical staining in brain tumor diagnosis include in alphabetical 
order carcino-embryonic antigen (CEA,positive example in metastatic carcinoma), 
chromogranin (Neuroendocrine tumor), cytokeratin (CK, metastatic carcinomas), 
epithelial membrane antigen(EMA, meningiomas), HMB-45(melanomas), 
Leukocyte common antigen (LCA, lymphomas), Placental alkaline phosphatase 
(PLAP, germcell tumors), S-100(Schwannomas), and synaptophysin (primitive 
neuroectodermal tumors) (Ackerman 1996). 
 
Glial fibrillary acidic protein (GFAP) is an intermediate filament specifically 
expressed in glial cells. This marker is a major constituent of glial cytoplasmic 
filaments, which helps to maintain and stabilize the glial cytoskeleton. It is present 
in normal, reactive, neoplastic astrocytes, ependymal cells, developing and 
neoplastic oligodendrocytes. 
 
Synaptophysin (SYN) a component of synaptic vesicle membrances expressed in 
normal neuropils in the gray matter and neoplastic well-differntiated neurons. It is 
negative in normal, reactive and neoplastic glial cells. 
 
Fibrillary astrocytoma 
 Low-grade astrocytomas represent only a small proportion of astrocytic 
tumors or gliomas in general. The reported proportions vary (8,37,43,54,59) at 
Newyork university (NYU) Medical center in the period 1977 thro 1998. Only 53 
examples were found in a retrospective review of more than  1500 adult gliomas in 
the neuropathology files. 
Sites:- 
 Grade I/III fibrillary astrocytomas are most common in the cerebral 
hemispheres (60% of pediatric examples) . In the cerebellum, diffuse low grade 
cerebellar tumors recur more frequently than their pilocytic counterparts17.26, 
overall the survival and functional outcome associated with cerebellar 
astrocytomas is excellent 24.32.52. In contrast, the term brainstem glioma usually is 
used to describe diffuse high-grade astrocytomas that infiltrate and expand the 
pons substantially; these tumors are associated with a poor prognosis. 4.5.39.50. 
 
 A review of a series of 100 children with intrinsic gliomas of the cord 
subjected to radical excision at NYU20 yielded 45 low-grade astrocytomas.35.36 
Gross – Mass lesion, Gray or white Matter with indistinct boundaries, small or 
large cyst, firmness. 
 
HPE – Mildly cellular tumor composed of fibrillar to stellate cells with minimal 
nuclear pleomorphism and lacking mitotic activity. 
IHC – GFAP Immunoreactive diffusely positive 
Gemistocytic astrocytoma 
 Variant of astrocytoma composed of variable fraction of Gemistocytic 
neoplastic astrocytes. Gemistocytes should be more than 20% of all tumor cells. 
Gemistocytic astrocytoma WHO Grade II or III lesions rapidly progress to 
globlastoma. 53 
IHC – Constantly express GFAP. 
Protoplasmic astrocytoma 
 Rare variant composed of neoplastic astrocytes showing a small cell body 
with few flaccid processes, low content of glial filaments and scant GFAP 
expression. 
 When occurring in children this neoplasm may be difficult to separate from 
pilocytic juvenile astrocytoma. 
 
Anaplastic astrocytoma 
 The peak age at which an anaplastic astrocytoma is diagnosed has been 
reported to be about 45 years.9.48  Patients under 40 to 45 years of age do much 
better than patients over that age, and patients over 60 to 65 do markedly worse 
than all younger patients.11.48 . 
 Gross- Solid tumor exhibiting friable, gray granular tumor tissue merging 
with the surrounding brain. Marked enlargement of adjacent gyri and basal ganglia 
HPE – Moderately to highly cellular tumor composed of fibrillar cells with IHC – 
GFAP – immunoreactive. 
Glioblastoma 
 It represents at least one quarter of all adult gliomas and over 15% of 
pediatric gliomas (including brainstem examples). In adults, the majority are 
encountered as cerebral hemispheric masses. Most often apparently centered in 
white matter. The peak age for adult patients is about 55 years, which is 
significantly different from that for the anaplastic astrocytoma. A cerebellar 
glioblastoma is uncommon in any group. 8.32.59 
      Gross- poorly delineated mass c/s – variegated appearance of red, brown, 
blacks, gray and white reflects hemorrhage. necrosis and expansion, often 
multifocality. Blurring of tumor/brain interfaces and gray white junctions 
obliterated by neoplastic tumors and associated edema. 
 
 HPE – Markedly cellular tumor composed of highly anaplastic pleomorphic 
cells with significant nuclear pleorphism. Vascular proliferation. mitotic activity 
and necrosis ( with or without) pseudopalisading tumor cells.  
IHC-GFAP multifocally reactive (may be scanty). 
 
Giant cell Glioblastoma 
Gross-well circumscribed. firm. Superficially located in the temporal and parietal 
lobes 
HPE- Glioblastoma with numerous multinucleated giant cells, small fusiform 
syncytial cells and reticulin network. 
IHC – GFAP expression is highly variable. 
Gliosarcoma 
Gross – Firm superficial mass 
HPE- a biphasic tissue pattern with areas displaying gliomatous or mesenchymal 
differentiation is essential. Neoplastic mesenchymal appearance and reticulin 
formation. 
 IHC- Gliomatous component shows strong GFAP expression, sarcomatous 
components show reticulin network. 
 
PilocyticAstrocytoma (PCA) 
 Pilocytic astrocytomas have been recorded from virtually all portions of the 
brain, but the large majority occurs in the cerebellum (usually in hemisphere) and 
the hypothalamus and related optic chiasma. cases localized to the deep gray 
matter ( thalamus, basal ganglia, cerebral white matter, brainstem, and spinal cord) 
are much less common. 
 
Gross-Soft, gray, discrete tumor mass with cyst formation is common 
 HPE- juvenile pilocytic astrocytic tumor of low cellularity exhibiting a 
biphasic pattern with bipolar cells, Rosenthal fibers, loose textural multipolar 
cells,  microcysts and granular bodies. 
 
 Adult PCA are formed of delicate elongated nuclei with their bipolar hair 
like fibrillar processes usually arranged  in a fascicular pattern. Microcystic areas 
and Rosenthal fibers are usually absent. They have a less favourable prognosis6 
than the juvenile type because they tend to infiltrate adjacent brain. 
IHC – Strong GFAP immunoreactivity highlights cytoplasmic processes. 
 
Pleomorphic Xantho Astrocytoma (PXA) 
Gross- PXA are attached to the meninges and accompanied by a cystic mural 
nodule within the cyst wall. 
 HPE- Tumor composed of fibrillary and giant multinucleated neoplastic 
astrocytes. Diagnostic hallmarks are large Xanthomatous cells, dense intercellular 
reticulin network and lymphocytic infiltration. Eosinophilic granular bodies 
present. 
IHC-GFAP Immunostaining of large plemorphic tumor cells. 
Oligodendroglioma 
 Oligodendrogliomas have incidence of 5  to 15%,  the true proportion may 
be low as 1%.8.40.59  Most olidendrogliomas are found in the hemispheric white 
matter. 
 Gross: -well defined soft masses of grayish pink color. Mucoid 
degeneration appear gelatinous. Calcification. cystic degeneration, and 
hemorrhage present.  
 HPE:- Moderately cellular and composed of tumor cells with rounded 
homogenous nuclei and on paraffin section a swollen clear cytoplasm 
 (Honeycomb appearance) 
.Micro calcification Mucoid / cystic degeneration and a dense network of 
branching capillaries, Microgemistocytes present. 
 IHC: - GFAP positive in mini gemistocytes and gliofibrillary 
oligodendrocytes, S-100 – diffuse and strong immuno reactivity. 
Anaplastic Oligodendroglioma:- 
 Gross: - Masses of Grey pink color, mucoid and cystic degeneration, 
calcification present. 
Hemorrhage and areas of necrosis seen. 
 HPE: - An oligodendroglioma with focal or diffuse features of malignancy 
such as increased cellularity, marked cytological atypia and high mitotic activity. 
Microvascular proliferation and necrosis may be present. Gliofibrillary 
oligodendrocytes and minigemistocytes are frequent. 
Oligoastrocytoma:- 
 Gross: - Well defined soft masses of grayish color. Mucoid degeneration 
appear gelatinous. Calcification, cystic change and hemorrhage present. 
 HPE:- A tumor composed of mixture of two distinct neoplastic cell types 
with micro calcification and microcystic degeneration present. It may be divided 
into biphasic and intermingled variants. It is important to differentiate between 
oligoastrocytoma and pure astroglial tumors because oligoastrocytoma responds to 
polychemotherapy.53 
IHC: - GFAP and vimentin expression are more consistently found in the 
astroglial component compared with a more variable expression in the 
oligodendroglial tumor cells. 
Anaplastic Oligoastrocytoma 
 Gross: - Masses with foci of necrosis and hemorrhages, cystic degeneration 
and calcification. 
 HPE: - Oligoastrocytoma with histological features of anaplasia. 
Ependymoma 
 In most large series, ependymomas are rather rare brain tumors, comprising 
fewer than 5% of all gliomas 46.56.59 . They are considerably more common in 
children, however, they represent almost 10% of gliomas14.21 and rank third behind 
PNET’s and astrocytomas in frequency. Spinal cord gliomas are uncommon, but 
among them the ependymoma is unusually prominent in adults. Ependymomas are 
likely to be the most common type of intramedullary spinal cord tumor.-15.46.56 
Gross: - Well demarcated, soft, grayish red tumor, necrosis and hemorrhage 
present. 
- In the spinal cord – Well defined, homogenous and granular tumor. 
HPE: - moderately cellular gliomas with a monomorphic nuclear morphology. 
Key histological features are perivascular pseudorosettes and ependymal rosettes. 
Myxoid degeneration, hemorrhage, calcification, occasionally foci of cartilage and 
bone formation. 
 
Variants : - Cellular ependymoma. Papillary ependymoma. Clear cell 
ependymoma and tanycytic ependymoma. 
 
IHC : - GFAP is typically weak throughout the tumor, with prominent   
pseudorosettes. 
 
Anaplastic Ependymoma  
In Children, fourth ventricular ependymomas are notorious for being refractory to 
therapy and producing a fatal outcome.   Supratentorial ependymomas in children 
carry a similar poor prognosis. In adults, surgical resection of spinal cord 
ependymomas is often curative and cerebral hemispheric tumors may have a 
prolonged and relatively favourable course because of their ready access to 
ventricular spaces.  Thus   ependymomas have some capacity to metastasize in the 
CSF to distant neuroaxial sites. 
 
HPE : - Ependymoma shws features of anaplasia.Perivascular rosettes are a 
histological hall mark but ependymal rosettes are absent. 
IHC : - Immunoreactivity resembles those of conventional ependymoma but 
GFAP expressions may be reduced. 
Myxopapillary ependymoma 
These tumors have a substantial incidence of CSF metastasis,but  they are rarely 
fatal.62 
 
Gross: - Encapsulated, lobulated soft and grayish appearance. 
 
HPE : -   Typically a papillary tumor with exaggerated myxoid change around 
blood vessels. Often exhibits long fibrillar process projecting through mucinous 
material to blood vessels. 
 
IHC : - GFAP typically weak through out the tumors with perivascular area 
exhibiting strong fibrillary reactivity. 
 
Subependymoma :  
Gross : - Firm nodules of variable size bulging into ventricular lumen.Well 
demarcated tumor. 
HPE : - Characterised by cluster of isomorphic nuclei embedded in a dense 
fibrillary matrix of glial cell processes with small cyst. Mitosis absent. 
IHC : - GFAP variable immunoreactive. 
 
Choroid Plexus Papilloma : 
Gross : - Circumscribed cauliflower – like masses that may adhere to the 
ventricular wall. but are well demarcated from the brain tissue. 
HPE : - Well differentiated papillary neoplasms in which cuboidal cells arranged 
in a single layer on thin delicate papillary fronds. No mitosis. 
Choroid Plexus Carcinoma :  
Gross : - Solid invasive tumor with hemorrhage and necrosis 
HPE : - Dysplastic cytological features including increased nuclear to cytoplasmic 
ratio, mitotic activity, pseudostratified appearance and loss of basal nuclear 
polarity. Also exhibits cellular invasion into cerebral parenchyma  with sheet like 
growth pattern. 
IHC : - Cytokeratin, Vimentin . S – 100 + ve  & GFAP focally Positive.      
Chordoid Glioma of third ventricle : 
HPE : - composed of clusters and cords of epithelial cells within  a  mucinous 
stroma. 
Stroma contain lymphoplasmacytic infiltration. 
Gliomatosis Cerebri. 
Gross : - Neoplastic growth and enlargement of involved structures without   any 
mass. 
Micro  - Elongated glial cells with hyperchromatic oval nuclei and increased 
mitotic activity. 
IHC – GFAP , S – 100 Positive. 
 
Neuronal & Mixed Neuronal – Glial Tumors. 
Ganglioglioma & Gangliocytoma :-  
Gross – Solid / Cystic tumor, no mass effect , calcification present. 
Gangliocytoma HPE : - Irregular groups of large multipolar neurons that show 
dysplastic features. Stroma shows reactive glial cells and network of reticulin 
fibers. 
Ganglioglioma HPE : - Additional neoplastic glial component surrounded by a 
reticulin network. 
Desmoplastic Infantile Ganglioglioma : 
Gross : - Large tumor involving superficial cortex and leptomeninges often 
attached to dura. 
HPE : - Desmoplastic stroma with entrapped astrocytes and / or neuronal cells. 
IHC – Glial cells express both GFAP and vimentin while neuronal differentiation 
is disclosed by synaptophysin. 
 
Dysembryoplastic neuroepithelial tumor 
Gross : - Intracortical , multinodular firm mass. 
HPE : - Typical glioneuronal element comprising microcystic spaces, 
oligodendrocyte  like cells and floating neurons often associated with cortical 
dysplasias. 
 
Central Neurocytoma :  
Gross : - Greyish and friable intraventricular tumor and calcified areas. 
HPE : - Small regular polyhedral cells with honey comb like arrangement,   round 
regular nuclei and pale cytoplasm. Micro calcifications are common. 
 
Pineal tumors 
Pineoblastoma : 
Gross : - Soft, friable, poorly demarcated tumor, hemorrhage and / or 
necrosis may be present. 
HPE : -   pineoblastomas are composed of pattern less sheets of densely 
packed small cells with round to irregular nuclei and scant cytoplasm. 
Pineocytomatous rosettes are lacking , but Homer – Wright and Flexner – 
wintersteiner rosettes may be seen. 
IHC : - Synaptophysin , Neuron Specific Enolase ( NSE ) and 
Chromogranin positive. 
 
Pineocytoma : - 
Gross : - Well circumscribed lesions, grey tan in colour. 
HPE : _ Composed of small uiniform mature cells resembling pineocytes. It 
grows primarily in sheets and also shows features of large pineocytomatous 
rosettes composed of abundant delicate tumor cell processes. 
IHC : - Synaptophysin , NSE & Neurofilament positive. 
Embryonal tumors  
Medulloepithelioma : 
Gross. – Well circumscribed tumor with areas of necrosis and hemorrhage. 
HPE : - Characterised by papillary, tubular / trabecular arrangement of neoplastic 
neuro epithelial cells with an external limiting membrane. 
IHC : - Nestin positive which is confined to the basal area. 
 
Ependymoblastoma :  
Gross : - Well circumscribed distinct tumor margin 
HPE : - Central primitive neuro ectodermal tumors with multilayered rosettes in 
which cells in the outer rim of the rosettes merge with the surrounding 
undifferentiated neuroectodermal cells. 
IHC : - S – 100 , Vimentin, Cytokeration and GFAP Positive. 
 
Medulloblastoma ( MB )  
Gross : - Circumscribed firm discrete mass. 
HPE : - densely packed cells with round to oval or carrot shaped hyperchromatic 
nuclei surroundred by scanty cytoplasm. Neuroblastic rosettes which consist of 
tumor cell nuclei disposed in a circular fashion around tangled cytoplasmic 
processes are typical. 
IHC : - Typically synaptophysin positive, GFAP positive rarely seen . S – 100 
variable.  
Variants – Desmoplastic MB . MB with extensive nodularity, Large cell MB , 
Medullomyoblastoma. Melanotic MB. 
 
Supratentorial primitive neuroectodermal tumor ( PNET ) 
Gross : - The parenchymal tumors may be massive growths with or with out cysts 
and hemorrhages. Demarcation between the tumor and the brain may range from 
indistinct to clear. 
Cut surface show soft. pinkish color. 
HPE : - are composed of undifferentiated or poorly differentiated neuroepithelial 
cells which may vary in their morphological features Cerebral suprasellar PNETs 
are basically similar to medulloblastoma. 
 
Atypical teratoid/rhabdoid tumor 
 
Gross – Soft pinkish red bulky neoplasm, hemorrhage and necrosis present. 
HPE – Rhabdoid cells with variable components of primitive 
neuroectodermal component. 
Mesenchymal and epithelial cells present. 
IHC – GFAP, Synaptophysin, EMA, Cytokeratin and NSE 
immunoreactive. 
 
Tumors of central and peripheral nerves. 
Schwannoma 
Gross – Globoid masses few cm to 10 cm in size. 
c/s Light tan glistening tissue interrupted by bright yellow patches. 
HPE-Tumor composed of spindle shaped neoplastic schwannian cells with 
alternating areas of compact elongated cells with nuclear palisading (Antoni A) 
and less cellular, loosely textured areas (Antoni B) palisading tumor cell nuclei 
called verocay bodies. 
Variants – Cellular. Melanotic and Plexiform. 
IHC-S-100 positive. Leu – 7 positive. 
Neurofibroma 
Gross – fusiform well circumscribed tumor 
c/s – firm glistening and grey-tan 
HPE – Composed of neoplastic Schwann cells, perineuronal like cells and 
fibroblast in a matrix of collagen fibers. 
IHC-S-100 Positive. 
Malignant peripheral nerve sheath tumor 
Gross-Globoid pseudoencapsulated tumor, firm to hard 
c/s Grey with foci of necrosis and hemorrhage. 
HPE-Typically a fibrosarcoma like fasciculated growth of tightly packed 
hyperchromatic spindle cells with abundant faint eosinophilic cytoplasm. 
Variants-Epitheloid, Glandular, Malignant Triton tumor. 
Meningeal tumors 
Cushing and Eisenhartdt, in their classic two volume monograph on meningiomas 
that was published in 1938, cited the prevalence of meningiomas as 13.4% of all 
intracranial tumors. The overall incidence of meningiomas reported in the 
literature ranged from 1 to 2.8 per 100.000 persons.58 
 Meningiomas in children are rare The hospital for sick children in Toronto 
reported an incidence of 13 meningiomas among 1283 intracranial tumors and an 
average age at presentation of 11.6 years. The female predominance of 
meningiomas seen in adults is absent in childhood.19 Studies in which CT or MRI 
was used revealed a peak incidence in the seventh decade of life58. In a recent 
autopsy series, the percentage of incidentally discovered meningiomas increased 
as age increased and was highest in people older than 80 years.47 
  
Malignant meningiomas tend to recur after complete resection at a much 
higher rate (70% within 8 years) than that of benign meningiomas  (up to 20% 
within 10 year).45,58 The extent of surgical resection is the critical determinant of 
survival45. 
 
Extra cranial metastasis from a meningioma is rare (0.1% of cases) but 
occurs more frequently in particular subtypes (e.g., 30% of papillary meningiomas 
metastasize).23 Sites of metastasis in decreasing order of frequency are as follows: 
lungs / pleura, musculoskeletal system, liver, reticuloendothelial system and 
kidneys.63. 
Benign meningioma 
Gross-Rubbery or a firm well demarcated rounded mass that have a broad dural 
attachment. 
HPE-Tumor cells form lobules which are surrounded by thin collagenous septae.  
Cells are uniform with oval nuclei, even chromatin and eosinophilic cytoplasm 
forming syncytium. 
IHC-EMA positive 
Atypical meningioma 
Gross-Large tumor with cystic change 
HPE-Sheeting pattern of tumor cells, brain invasion, necrosis, nuclear 
pleomorphism, prominent nucleoli and increased mitotic activity. 
Malignant meningioma 
HPE-features of atypical meningioma with increased mitotic activity. 
IHC – EMA positive, Vimentin, S-100 positive, CEA and cytokeratin positive. 
Hemangiopericytoma 
Gross-Solid well demarcated tumor, tendency to bleed during surgery. 
Cut surface fleshy grayish to red brown. 
HPE-Highly cellular monotonous tumor composed of plump cells with scant 
cytoplasm accompanied by numerous small vascular spaces and dense network of 
reticulin fibers. 
IHC-Vimentin and factor 13A positive. 
 
Malignant lymphoma 
Gross-Single or multiple masses in the cerebrum, firm friable gray yellow with 
central necrosis. 
HPE-Lymphoma that diffusely infiltrates the brain parenchyma in an angiocentric 
pattern forming collar of tumor cells within concentric perivascular reticulin 
deposits. 
Variants –B-cell lymphoma. T-cell lymphoma. Plasmacytoma. Angiotrophic 
lymphoma, Hodgkin disease, MALT lymphoma of dura. 
Germ cell tumors 
Germinoma-Solid, soft, friable, tan white tissue 
IPE-Composed of uniform cells resembling primitive germ cells with large 
vesicular nuclei, prominent nucleoli and lymphoplasmacytic cellular infiltrations. 
 
Teratoma 
Gross-Mucous laden cysts, fat, chondroid nodules or bony spicules, Rarely well 
formed hairs or teeth. 
 
Mature teratoma 
Composed of fully differentiated adult type tissue elements arranged in a pattern 
resembling normal tissue. 
Immature teratoma 
Composed of incompletely differentiated components resembling fetal tissues. 
 
Yolk sac Tumor 
Composed of primitive appearing epithelial cells set in a loose, variably cellular 
and myxoid matrix resembling extra embryonic mesoblast. Eosinophilic hyaline 
globules. 
IHC-immunoreactive for AFP 
Embryonal Carcinoma 
Composed of large cells that proliferate in cohesive sheets and nest, form abortive 
papillae or gland like spaces. Tumor cells replicate the structure of the early 
embryo forming embryoid bodies. 
 
Choriocarcinoma 
Gross-extensive hemorrhagic necrotic tissue 
HPE-Characterized by extra embryonic differentiation along the trophoblast. 
Diagnosis requires the identification of cytotrophoblastic elements and syncytio 
trophoblastic giant cells. 
 
Tumors of Sellar region 
Craniopharyngioma 
Gross-Well demarcated solid tumor with cystic component, calcification, cyst 
contains cholesterol rich, machine oil like, thick brownish yellow fluid. 
HPE-Consist of strands of ameloblastic epithelium with peripheral palisading of 
nuclei. Diagnostic features are nodules of compact wet keratin and dystrophic 
calcification.53 
IHC-High Molecular Weight Keratins and Low Molecular Weight Keratins 
positive. 
 
Pituitary adenoma (tumor of the adenohypophysis) 
Gross-Well circumscribed, with soft consistency.  
Cut surface shows-grey to yellow homogenous or granular 
HPE-Consist of densely packed polygonal cells with abundant cosinophilic 
granular, PAS-positive cytoplasm. 
For practical purposes pituitary adenomas may be divided into endocrine-active 
and endocrine-inactive tumors.59,66 
Metastatic tumors of the CNS 
Gross-Discrete round or well circumscribed grey white or tan masses. Tumors 
attached to the dura or leptomeninges may form nodules. Hemorrhage may be 
seen. 
 
HPE-Metastasis are similar to those of the primary tumor from which they arise. 
Tumor necrosis is frequent with well-defined borders with the adjacent 
parenchyma and displace, rather than infiltrating the tissue as they enlarge. 
  
Brain tumors can be diagnosed by CT scan and MRI images. 
 
Cell proliferation markers 
The cell proliferation markers are – Bromodeoxyuridine (BrdUL). Ki67 and 
Proliferating cell nuclear antigen (PCNA). Out of these BrdUL and Ki67 are more 
consistent and their results can be correlated with each cycle. These two antibodies 
give a fairly good idea about the cell cycle. 
 
The above two markers correlate well with tumor grade and survival. 
Higher the value of these two antibodies, worse is the prognosis. The 
interpretation of any immunohistochemistry results should always be done in 
accordance with the morphology and proper clinical and radiological correlation. 
 
 
  
 
 
 
 
 
 
 
AIM OF THE STUDY 
 
 
 
 
 Specimens were studied to find out:- 
 
1. The incidence of CNS neoplasms. 
2. To evaluate the anatomical distribution of CNS neoplasms. 
3. To evaluate the histopathological features with light microscopy and 
special stains. 
4. To grade the CNS neoplasms according to guide lines provided by the 
World Health Organization [WHO]. 
5. To evaluate the role of immunohistochemical markers in CNS tumors for 
confirmation and arriving at final diagnosis.        
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 In this prospective study of CNS neoplasms which covered 83 cases 
during March 2007 – March 2009, the overall incidence of CNS neoplasms 
encountered by others was less than 9% (CBTRUS data) and in my observation it 
was 9.97% 
 
 Incidence of various CNS neoplasms is compared with the central brain 
tumor registry of United States. (CBTRUS study) 2004 – 2005 which is exhibited 
in the following table. 
 
 Astrocytoma Oligodendroglioma Ependymoma Meningioma Neural Tumors Craniopharyngioma
CBTRUS 
Study 
41.2% 3.2% 2.3% 24% 6.5% 0.9% 
Recent 
Study 
41 Cases 
49.3% 
1 Case 
1.2% 
1 Case 
1.2% 
15 Cases 
18.1% 
7 Cases 
8.4% 
2 Cases 
2.4% 
 
 Our study in accordance to CBTRUS  study(14) shows that astrocytomas 
still remain to be the commonest CNS neoplasm (49.3%) followed by 
meningiomas 18.1%. This table also illustrates that nerve sheath tumors are 
common neoplasms found in our set up with a slightly higher incidence of 8.4% 
 
 Brain tumor incidence tends to be higher in countries with more 
developed medical care. Although there is no population that is not at risk for 
developing glioma there is some correlation between incidence and characteristics 
such as age, gender, ethnicity and geography according to Nicholas A Butoneski 
& Susam M. Chang et al(43) 
 
 This study shows that CNS Neoplasm are commonly seen between the 
age groups 31 – 40 yrs ( 30.1%) followed by 41 – 50 Yrs ( 21.6%). CNS 
neoplasms are least commonly seen in the elderly age group i.e between 61 – 70 
yrs (3.6%).   This was in accordance with the study of Paul - Kleihaus et al (47) In 
contrast to the same associates who said that CNS neoplasms were slightly higher 
in males (1.8: 1), our study revealed a slightly higher incidence in females 46 
cases (55.4%).  
 
 The commonest site of CNS neoplasm in this study occurred in the 
parietal lobe 27 cases  - (32.5 % ) followed by frontal lobe 25 cases (30.1 %). 
 
 Grading is done for all CNS neoplasms according to the World Health 
Organisation norms. Grading follows the same guidelines with the Daumas Duport 
grading system as quoted by Roger. E. Mc Lendon et al.(53)  
 
 In this system, one point is accorded to the presence for each of nuclear 
pleomorphism, mitotic activity, vascular proliferation and necrosis. 
  
 zero or  1 point correlates with WHO grade II 
   2 points correlates with WHO grade III 
   3 – 4 points correlates with WHO grade IV 
  
                While cellular density is not considered in grading, cellular density is a 
consideration in establishing a diagnosis of neoplasia in the sense that the 
formation of a tumor is derived solely through the uncontrolled replication of 
cells. According to the study of Peter et al. (50), the incidence of various CNS 
neoplasms according to age show  
 
  Grade II – 3rd to 4th decade  
  Grade III – 5th decade 
  Grade IV – 6th decade 
  
 Our study showed that grade I neoplasms were in accordance with the 
above study whereas grade II and grade IV neoplasms in contrast were seen in 3rd 
and 5th decades respectively. 
 
 Sex wise ratio showed that females outnumbered males in grades I, II 
and IV whereas grade III neoplasms were predominated by males. 
 Comparative analysis of incidence of glial tumors studied at various 
institutions in India with our study was done (41). 
 
S.No Study Astrocytoma Glioblastoma Medulloblastoma Oligodendroglioma Ependymoma 
1 
Tata 
Memorial 
Hospital, 
Mumbai 
46.3% 21.5% 11.1% 6.3% 6.8% 
2 
Kidwai 
Memorial 
Institute of 
Oncology, 
Bangalore 
41.1% 22.95% 11.2% 9.6% 1.92% 
3 
Cancer 
Institute , 
Adayar, 
Chennai 
39% 29.05% 5.9% 4.4% 3.4% 
4 
Regional 
Cancer 
Institute, 
Trivandrum 
41.35% 13.3% 12.7% 3.35% 2.1% 
5 
Assam 
Medical 
College, 
Dibsugarh 
46.75% 7.1% 8.1% 9.1% 7.1% 
6 Present 
Study 
49% 9.6% 4.8% 1.2% 1.2% 
 
 The above table shows that astrocytomas constitute the major chunk of 
gliomas in our study consistent with studies conducted by other institutions(41 
cases – 49%). 
 
 Of the 41 cases of the astrocytomas diagnosed there were 3 cases of 
grade I astrocytoma with an incidence of 7.3%. All the three cases, showed only 
an increase in cellularity. The three cases occurred in the middle age group with a 
slight increase in males (2:1). 
 
 According to the studies of Paul Kleihaus et al.(47) diffuse astrocytomas 
is the commonest of all astrocytomas, commonly occurring in the middle age 
group. Our study too showed consistent features (16 cases – 39.02%) with diffuse 
astrocytomas in the age group of 31- 40 years. According to the same associates, 
long term follow up studies have shown that with maximum tumor decompression, 
followed by adequate adjuvant therapies the mean survival of grade II 
astrocytomas is more than 10 years. 
 
 Anaplastic astrocytomas constitutes about 14 cases(34.1%) with peaks 
between 31 – 40 years and 51- 60 years, according to Paul Kleihaus et al.(47) Mean 
survival of grade II astrocytomas varied from 2-5 years. Studies of Watanahe. K. 
Sato et al(62)., showed that the progression of anaplastic astrocytoma to 
glioblastoma was a key prognostic factor, with a mean of 2 years. Approximately, 
10 % of grade III anaplastic astrocytomas show expression of Epidermal Growth 
Factor Receptor. Cellular proliferation occurs by activation of a tyrosine kinase 
receptor, platelet derived growth factor and Vascular Endothelial Growth 
Factor(VEGF). VEGF is involved in the pathways that determine endothelial 
proliferation and neovascularisation. 
 
 Grade IV astrocytomas in the present study, constitute 8 cases(19.5%) 
of all astrocytomas and 9.6% of all intracranial tumours in contrast to the studies 
of Zulch KJ et al. (64) who said that glioblastoma accounted 12 – 15 % of all 
intracranial neoplasms and 50 – 60 %  of all astrocytic tumours. 8 cases occurred 
in varying age groups peak being between 51 – 60 years, consistent with the 
studies of Zulch KJ et al. (64) who gives peak incidence between 45 – 70 years. All 
cases showed necrosis and endothelial vascular proliferation. 
 
  Regarding the sex-wise ratio of astrocytomas, our study showed a 
slight preponderance of males to females. With respect to grades, females 
outnumbered males in grade II and IV whereas males in grade I and III. 
 
 Meningiomas comprised the second largest group of neoplasms in this 
study with 15 cases constituting 18.1 % of all CNS neoplasms comparable to 
CBTRUS study(14) and studies done by Lantos PL Vandenberg et al.(30) who gives 
an incidence of 13.26 % of all intracranial tumors.  
 
 All the cases were graded on the basis of WHO norms which included 
cellularity, pattern, mitosis and necrosis. Out of the 15 cases, 14 cases (93.3%) 
were diagnosed as grade I meningiomas with varying histological patterns. 
Features of atypia or anaplasia were not evident in any of the above cases. No 
atypical meningiomas were seen in the study. 
 
 Only one anaplastic meningioma was seen with an incidence of 6.6% of 
all meningiomas in contrast to the study of Jaerkelainen et al.(28) who gives an 
incidence of  1 – 2.8%. 
 
 According to studies of Paul Kliehaus et al.(47) meningiomas are 
common in the 6th to 7th decade with a predilection to females. In contrast our 
study showed a higher incidence of meningiomas between 3rd to 4th decade but 
were commonly seen in females. [9 cases-60%]. As per the study of Perry. A 
Stafford et al.(49) meningiomas in children behave very aggressively. In our study 
there was no such incidence in children. 
 
 Neural tumors were the next common group encountered in the present 
study. As per studies conducted by Cassedi et al. (13) neural tumors constitute 8% 
of all intracranial tumors with higher incidence in 4th to 6th decade and female to 
male ratio being 2:1. Our study also showed consistent features with an incidence 
of 8.4% of all intracranial tumors [7 cases] commonly seen between 3rd to 4th 
decade with a slight increase in females [4 cases out of 7 – 66%]. Schwannomas 
were the commonest of neural tumors seen in the study, commonest site of 
occurrence being the cerebellopontine angle 5 out of 7 cases [71.4%] consistent 
with the studies of Cassedi et al. (13)  
 
Pediatric Neoplasms 
 
 Incidence of pediatric CNS neoplasm was found to be 9 – 10 % by other 
workers such as CBTRUS study(14) and Rusell DS Rubinstein et al. (55) but in our 
study it was 13.2%. However the limitation in the present study is the small 
number of cases encountered in the pediatric age group. Medulloblastoma was the 
commonest CNS neoplasm in pediatric population seen in our study. Sex wise 
ratio of pediatric CNS tumors is compared with the studies conducted by various 
institution in India (41). 
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  Comparative study shows that pediatric CNS neoplasms in other 
institutions as well as in our study [7 cases-13.2%] are commonly seen in female 
children as illustrated in above bar diagram. With respect to grading grade IV 
neoplasms are frequently encountered in children. 
 
 Among the pediatric neoplasms as quoted earlier, medulloblastoma was 
the commonest neoplasm with an incidence of 4.8% of all intracranial tumors and 
36.36% of all pediatric intracranial neoplasms [4/11 cases]. This showed a slight 
variation with the studies of Mahaley. M. Metilen et al. (36) who gives an incidence 
of 3% of primary CNS tumors and that of Rutka. J.T et al.,(56) an incidence of 25% 
of all intracranial neoplasms.  
 
 As quoted by Paul Kleihaus et al. (47) medulloblastoma occurs more 
commonly between 0 -10 Yrs [Peak 7yrs] with a slight predilection in males.  
  
 Our study too showed that all the 4 cases seen were less than 10 years 
but with regard to sex wise ratio, showed an equal distribution.                
 
 Medulloblastoma is a highly malignant primary tumor that originates in 
the cerebellum or posterior fossa. i.e. infratentorial as studied by Coffin GM Braun 
et al. (15) This feature was consistent with our study which showed that all 
medulloblastomas originated in the infratentorial region.  
 
 The other common neoplasm seen in pediatric population was 
craniopharyngioma. According to Bunin GR Surawick et al.,(8) craniopharyngioma 
constitutes 1.2 – 4.6% of all intracranial neoplasms which was in accordance with 
our study showing an incidence of 2.4%. In contrast to the same associates who 
give an incidence of 5 – 10% of all intracranial tumours in children, our study 
showed a higher incidence of 18.1%. As per studies of Adamson T.E. et al(3), 
histologically papillary craniopharyngiomas were common in adults and 
adamantinomatous variant in children. The two cases in our study showed 
adamantinomatous type of craniopharyngioma consistent with the literature.  
 
 We have seen one case of choroid plexus papilloma in the pediatric age 
group which showed an incidence of 1.2% of all brain tumours and 9.09% 
incidence in children in contrast with the study of Janish. W. Staneczek et al.(29) 
who gives an incidence of 0.4 - 0.6% of all brain tumors and 2.4% in children. The 
site was the ventricle which was consistent with the literature.  
 
 The other neoplasm seen in children was oligodendroglioma. As per the 
study of Paul Kleihaus et al(47), oligodendroglioma was found to be around 6% of 
all intracranial tumours in childhood with a mean age of 10 years for 
supratentorial cases. The above observation shows a variation with our study 
which gives an incidence of 1.2% of all intracranial tumours. The only one case 
seen was in a female child, site being the supratentorial region.  
 
 The other tumor seen was an astrocytoma of grade II with an incidence 
of 0.9% of all intracranial neoplasms. According to J. Thomas Stocker Louis. P. 
Dehner et al.(61) low grade astrocytomas show an incidence of 37% in the pediatric 
population. Studies of Roger. E. Mc Lendon et al.(53) says that well differentiated 
fibrillary astrocytoma are unusual in small children and constitutes approximately 
30% of all astrocytomas in pediatric age group. Studies done by Paul Kleihaus et 
al.(47) have suggested an increasing incidence of astrocytomas in children during 
the past three decades.  
 
 Metastatic tumors comprised the next major group of neoplasms in our 
study. There were 5 cases in our study which gives an incidence of 6.03% of all 
intracranial neoplasms. All the 5 cases were seen in females between the 2nd and 
5th decade. This is in contrast with the studies of Paul Kleihaus et al.(47) who gives 
an annual incidence of 0.03 to 0.04% with rate of metastasis higher in elderly age 
group. But the sex-wise ratio was consistent with the literature. The probable site 
of the primary was known in 3 cases.  
  
 The other CNS neoplasms encountered in our study were pituitary 
adenomas with an incidence of 2.4% which was in contrast with the studies of 
Cotran Robins et al.(52) who gives an incidence of 10% of all intracranial 
neoplasms with a peak in 30 – 50 years of age in females. Our two cases were in 
the age group of 11 – 20 years and 41 – 50 years, with both being in the female 
population.  
 
In our study we had 4 cases which were difficult to arrive at a diagnosis 
based on histopathology alone. Hence further evaluation was done with special 
stains and immunohistochemistry. 
 
 The utility of special stains and immunohistochemistry in the diagnosis of 
CNS neoplasms is well documented.(18) However it is to be noted that results of 
these specialized staining techniques should be interpreted with caution in the light 
of findings noted on routine H & E sections. 
 The present study evaluates the usefulness of special stains like PAS and 
reticulin in 2 cases, which only has complemented the diagnosis already arrived. 
 A case of chordoma was seen in our study in a 47 years old male in the 
right frontoparietal region which was confirmed by light microscopy. A PAS stain 
was done to demonstrate the presence of mucin in the physalliferous cells.  
 Reticulin was applied to a case diagnosed as Gliosarcoma / Lymphoma and 
found that reticulin showed positivity around individual cells. The diagnosis was 
further confirmed by immunohistochemistry. 
 Immunohistochemistry was done for problematic cases using a panel of 
antibodies which is depicted in Table  No.22 
 The case diagnosed as Gliosarcoma / Lymphoma histopathologically 
showed positivity for GFAP and negativity for CD40, hence a final diagnosis of 
gliosarcoma was arrived. 
 2 cases showed positivity for synaptophysin where one was diagnosed as a 
small cell variant of GBM and another broad diagnosis of SRBCT under light 
microscopy, hence arriving at a diagnosis of Primitive Neuroectodermal tumor for 
both. 
 Another interesting case was given a spectrum of differential diagnosis as 
Rhabdomyosarcoma / Malignant Histiocytosis / Lymphoma based on histology. 
Immunohistochemistry using a panel of antibodies helped in differentiating the 
three. The above case showed positivity for CD68 whereas negativity for desmin 
and CD40, left with the diagnosis of Malignant histiocytosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHOD 
 
  Out of 9629 cases reported totally, 83 central nervous system neoplasm 
diagnosed clinically were received from Thanjavur Medical College and Raja 
Mirasudhar Hospital which is affiliated to Thanjavur Medical College. Specimens 
received during March 2007 to March 2009 are included in this study. Cases 
diagnosed as neoplasms are included, reactive lesions are excluded from this 
study. 
 
  The specimens received were mostly biopsies as an aggregate ranging from 
0.5cc to 5cc. Only 2 specimens, one a case of meningioma measuring 5x4 cms 
and a case of chordoma measuring 6x4 cms were received. Multiple bits were 
taken from the tumor masses. 
 
  A detailed history with particular attention to clinical symptoms and signs 
were noted. Site of the tumors were recorded, correlating with the computed 
tomography findings. A thorough gross examination of the specimens were done. 
Histopathological Study of CNS Neoplasms 
 
  All the specimens were fixed in 10% neutral formalin and were subjected to 
histopathological examination. Sections of 3-5 micron thickness were made and 
routine staining with Haematoxylin and eosin was done.(Appendix I)  
 
  Histochemical stains like Reticulin and Periodic Acid Schiff were applied 
in 2 cases for confirmation. (Appendix II, III) 
 
  Immunohistochemistry was done with a panel of antibodies in doubtful 
cases using Glial fibrillary Acid protein, Synaptophysin, desmin, CD40 and CD 
68.(Appendix IV) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 OBSERVATIONS AND RESULTS 
INCIDENCE : 
 
The annual incidence of CNS neoplasms in our study is 9.97 % ( 83 cases ) which 
is illustrated in table no .1. 
Table-1 
 
Incidence of CNS neoplasms in our study 
Period Total No.of Specimens 
Total 
Neoplasms 
CNS 
Neoplasms Incidence
March 2007 
To 
February 
2008 
4956 425 44 10.3% 
March 2008 
To 
March 2009 
4673 407 39 9.5% 
Total 9629 832 83 9.97% 
 
AGE INCIDENCE: 
 
The tumors are grouped according to the age at presentation ( ie.1-10 yrs,11 – 20 
yrs,21 – 30 yrs, 31 – 40 yrs,41 – 50 yrs, 51-60 yrs and 61 – 70 yrs ) 
Table -2 
AGE & SEX WISE INCIDENCE CNS TUMOURS 
Age in Years Male Female 
1-10 4 6 
11-20 2 6 
21-30 3 4 
31-40 11 16 
41-50 10 8 
51-60 5 6 
61-70 2 1 
Total 37 46 
 
 Table.2 (Fig33) shows that CNS tumors occur more frequently in the age group of 
31-40 yrs [27 cases,32.5%] followed by 41-50 yrs [18 cases, 21.6%]. Least no. of 
cases is seen in the age of 61 – 70 yrs [3 cases, 3.6%] followed by 11-20 yrs [8 
cases,9.6%] This table also shows a slight preponderance in females [46 cases, 
55.4%] whereas males show an incidence of 37 cases - 44.6%. 
 
GRADING : 
 
Grading is done for tumors according to the age based on WHO norms. This 
includes all CNS neoplasms [neuroepithelial, meningeal, schwannian and 
embryonal]. This is illustrated in the Table given below. 
 
Table-3 
 
WHO GRADING WITH RESPECT TO AGE GROUP [75 CASES] 
 
Grades 1-10 
Yrs 
11-20 
Yrs 
21-30 
Yrs 
31-40 
Yrs 
41-50 
Yrs 
51-60 
Yrs 
61-70 
Yrs 
I 3 1 3 11 6 3 1 
II 1 2 1 7 6 1 1 
II - 3 2 5 - 4 1 
IV 4 1 - 2 3 3 - 
 
 
Table 3 shows that grade I, grade II and grade III neoplasms are common in the 3rd 
– 4th decade where as grade IV neoplasms occur in peaks in the Ist decade and 5th 
to 6th decade. Least no. of tumors are seen in the 6 -7th decade. 
Table- 4 
 
INCIDENCE OF CNS NEOPLASMS – WHO GRADE 
 
Grade No. of Cases percentage
I 28 37.2% 
II 19 25.3% 
III 15 20% 
IV 13 17.3% 
 
This is followed by table.4 (Fig34) which shows that most of the CNS neoplasms 
in this study are in grade I [28 cases,37.2%] followed by grade II neoplasms [9 
cases,25.3%]. Least no. of cases are seen in grade IV [13 cases,17.3%]. 
 
Table-5 
GRADING AND SEX WISE INCIDENCE OF CNS NEOPLASMS 
Grade Male percentage Female Percentage 
I 10 35% 18 64% 
II 8 42% 11 57% 
III 11 73% 4 26% 
IV 4 30% 9 59% 
Total 33 44% 42 56% 
 
Our study show an increased incidence of CNS tumors in females [42 cases,56%] 
and males [33 cases,44%] which is exhibited in table no.5.(Fig.35). This table also 
shows that females out number males in grade I [18 cases,64%]. Grade II [11 
cases,57%] and grade IV [9case-59%] respectively where as grade III neoplasms 
are predominated by males [11 cases, 73%]. 
 
Table-6 [83 Cases] 
 
INCIDENCE OF VARIOUS CNS NEOPLASMS 
 
S.No HPE Diagnosis No A Cases No of Cases % 
1. Astrocytomas 41 49% 
2. Meningioma (Fig.1) 15 18.1% 
3. Medulloblastoma 4 4.8% 
4. Ependymoma 1 1.2% 
5. Oligodendroglioma 1 1.2% 
6. Craniopharyngioma 2 2.4% 
7. Neural Tumors 7 8.4% 
8. Pituitary Adenoma 2 2.4% 
9. Choroid plexus papilloma 1 1.2% 
10 Metastasis 5 6.3% 
11 Others 4 4.8% 
 
 
Table.6 (Fig.36) depicts the incidence of various histological types of CNS 
neoplasms seen in our study. Astrocytomas constitute the most common neoplasm 
[41 cases, 49.3%] followed by meningiomas [15 cases, 18.1%], neural tumors [7 
cases, 8.4%], metastatic tumors [5 cases,6.03%] and medulloblastomas [4 
cases,4.8%]. Least commonly seen tumors in our study are craniopharyngiomas 
and pituitary adenomas [2 cases each 2.4%] followed by ependymoma (Fig.13), 
oligodendroglioma and choroid plexus papilloma [1 case each, 1.2%]   
 
 
Table-7 
AGE WISE INCIDENCE OF CNS NEOPLASMS 
 
Grades 1-10  Yrs 
11-20 
Yrs 
21-30 
Yrs 
31-40 
Yrs 
41-50 
Yrs 
51-60 
Yrs 
61-70 
Yrs Total 
Astrocytoma I&II 1 1 3 4 6 3 1 19 
Astrocytoma III&IV - 4 1 7 2 7 1 22 
Meningioma I - - 2 7 3 1 1 14 
Meningioma II&III - - - 1 - - - 1 
Oligodendroglioma - 1 - - - - - 1 
Ependymoma - 1 - - - - - 1 
Medulloblastoma 4 - - - - - - 4 
Craniopharyngioma 2 - - - - - - 2 
Pituitary Adenoma - 1 - - 1 - - 2 
Choroid Plexus 
Papilloma 1 - - - - - - 1 
Deposits - - 2 1 2 - - 5 
Schwannoma - - - 4 1 1 - 6 
Neurofibroma - - - 1 - - - 1 
Gliosarcoma/Lymphoma - - - - 1 - - 1 
Anaplastic Lymphoma 1 - - - - - - 1 
SRBCT 1 - - - - - - 1 
Chordoma (Fig.2,22,23) - - - - 1 - - 1 
Total 
 
83 
Cases 
 
 
Table.7 shows the age wise incidence of CNS neoplasms. In the age group of 1-10 
yrs medulloblastoma is most common followed by craniopharyngioma. 
Astrocytoma is the frequently seen neoplasm in the age group of 11-20 yrs and 21-
30 yrs. In the age group of 31-40 yrs and above astrocytoma and meningioma are 
the most commonly seen neoplasms. 
 
Table-8 
WHO GRADING FOR ASTROCYTOMAS [41/83 CASES] 
 
S.No Pathology No HPE Diagnosis Increased Cellularity Nuclear Atypia Mitosis 
Microvascular 
Proliferation&Necrosis Grade
1.  99/07 Anaplastic Astrocytoma +ve +ve +ve -ve III 
2.  188/07 Glioblastoma Multiforme +ve +ve +ve +ve IV 
3.  300/07 Anaplastic Astrocytoma +ve +ve +ve -ve III 
4.  471/07 Diffuse Astrocytoma +ve +ve -ve -ve II 
5.  1156/07 Astrocytoma +ve -ve -ve -ve I 
6.  1204/07 Diffuse Astrocytoma +ve +ve -ve -ve II 
7.  1271/07 Glioblastoma Multiforme +ve +ve +ve +ve IV 
8.  1636/07 Anaplastic Astrocytoma +ve +ve +ve -ve III 
9.  1641/07 Glioblastoma Multiforme +ve +ve +ve +ve IV 
10.  1674/07 Anaplastic Astrocytoma +ve +ve +ve -ve III 
11.  1721/07 Astrocytoma +ve -ve -ve -ve I 
12.  1831/07 Diffuse Astrocytoma +ve +ve -ve -ve II 
13.  2172/07 Glioblastoma Multiforme +ve +ve +ve +ve IV 
14.  2431/07 Diffuse Astrocytoma +ve +ve -ve -ve II 
15.  2489/07 Diffuse Astrocytoma +ve +ve -ve -ve II 
16.  2691/07 Diffuse Astrocytoma +ve +ve -ve -ve II 
17.  2738/07 Glioblastoma Multiforme +ve +ve +ve +ve IV 
18.  3053/07 Anaplastic Astrocytoma +ve +ve +ve -ve III 
19.  3085/07 Diffuse Astrocytoma +ve +ve -ve -ve II 
20.  83/08 Anaplastic Astrocytoma +ve +ve +ve -ve III 
21.  293/08 Anaplastic Astrocytoma +ve +ve +ve -ve III 
22.  550/08 Diffuse Astrocytoma +ve +ve -ve -ve II 
23.  726/08 Glioblastoma Multiforme +ve +ve +ve +ve IV 
24.  855/08 Anaplastic Astrocytoma +ve +ve +ve -ve III 
25.  874/08 Anaplastic Astrocytoma +ve +ve +ve -ve III 
26.  1416/08 Anaplastic Astrocytoma +ve +ve +ve -ve III 
27.  1541/08 Diffuse Astrocytoma +ve +ve -ve -ve II 
28.  1542/08 Anaplastic Astrocytoma +ve +ve +ve -ve III 
29.  1922/08 Glioblastoma Multiforme +ve +ve +ve +ve IV 
30.  1943/08 Anaplastic Astrocytoma +ve +ve +ve -ve III 
31.  2122/08 Anaplastic Astrocytoma +ve +ve +ve -ve III 
32.  2253/08 Diffuse Astrocytoma +ve +ve -ve -ve II 
33.  3063/08 Diffuse Astrocytoma +ve +ve -ve -ve II 
34.  3118/08 Glioblastoma Multiforme +ve +ve +ve +ve IV 
35.  3133/08 Diffuse Astrocytoma +ve +ve -ve -ve II 
36.  3516/08 Astrocytoma +ve -ve +ve -ve I 
37.  24/09 Diffuse Astrocytoma +ve +ve -ve -ve II 
38.  179/09 Diffuse Astrocytoma +ve +ve -ve -ve II 
39.  407/09 Anaplastic Astrocytoma +ve +ve +ve -ve III 
40.  649/09 Diffuse Astrocytoma +ve +ve -ve -ve II 
41.  700/09 Diffuse Astrocytoma +ve +ve -ve -ve II 
 
Astrocytomas are graded according to the WHO grading system which includes 
cellularity, nuclear atypia, mitosis and microvascular proliferation/necrosis as 
shown in the following table. 
Table-9 
Incidence of grades of Astrocytoma [41 / 83 cases] 
 
Grade No.of Cases Percentage 
I 3 7.3% 
II 16 39.02% 
III 14 34.1% 
IV 8 19.5% 
 
Table.9.(Fig.37) shows that most of the astrocytomas are of grade II (Fig.4) [16 
cases,39.02%] followed by grade III(Fig.5) [14 cases, 34.1%]. Grade IV (Fig.6) 
astrocytomas, show an incidence of [8 cases 19.5%]. Least cases are seen in grade 
I (Fig.3) [3 cases,7.3%]. 
 
Following table No. 10 (Fig.38) shows the age wise incidence of astrocytoma. The 
3 cases of grade I astrocytomas are seen in varied age group from 31-60 yrs. Grade 
II astrocytomas are seen in the age group of 31 -40 yrs, grade III in 31 -40yrs 
followed by 51-60 yrs. Grade IV astrocytomas frequently seen in the age group of 
51 – 60 yrs. 
 
Table No.10 
 
Age wise incidence of astrocytomas 
 
Grade 1-
10Yrs 
11-20 
yrs 
21-
30Yrs 
31-40 
Yrs 
41-50 
Yrs 
51-60 
Yrs 
61-70 
Yrs 
I - - - 1 1 1 - 
II 1 1 1 7 4 1 1 
II - 3 2 4 - 4 1 
Iv - 1 - 2 2 3 - 
 
 
 
Table No.11 
Sex wise incidence of astrocytomas  
 
Grade Male Female 
I 2 1 
II 7 9 
III 10 4 
IV 3 5 
Total 22[53.6%] 19[46.3%]
Table .11 illustrates the sex wise incidence of astrocytomas, This study shows a 
slight increased incidence in males [22 case,53.6%]. 
Table No -12 
 
WHO Grading System – Meningioma  [15/83 cases] 
 
S.No Pathology Numbers HPE Diagnosis 
Increased 
Cellulity 
Sheeting 
Pattern 
Increased 
Mitosis Grading
1. 920/07 Conventional Meningioma N -ve -ve I 
2. 1537/07 Psammomatous Meningioma (Fig.10)   N -ve -ve I 
3. 2232/07 Transitional Meningioma N -ve -ve I 
4. 348/08 Conventional (Fig.7) Meningioma  N -ve -ve I 
5. 397/08 Transitional (Fig.8) Meningioma  N -ve -ve I 
6. 573/08 Fibrous Meningioma (Fig.9) N -ve -ve I 
7. 684/08 Conventional Meningioma N -ve -ve I 
8. 850/08 Conventional Meningioma N -ve -ve I 
9. 1415/08 Transitional Meningioma N -ve -ve I 
10. 1494/08 Anaplastic Meningioma (Fig.12) ↑ +ve +ve III 
11. 1592/08 Transitional Meningioma N -ve -ve I 
12. 1651/08 Transitional Meningioma N -ve -ve I 
13. 1672/08 Fibrous Meningioma  N -ve -ve I 
14. 2160/08 Conventional Meningioma N -ve -ve I 
15. 2236/08 Angiomatous (Fig.11) Meningioma N -ve -ve I 
 
Likewise meningiomas are also classified according to WHO grading system as 
shown in the following table.12. 
 
This table shows that 14/15 cases are in grade I with an incidence of 93.3% of 
varying histological patterns. One case with anaplastic features like increased 
cellularity, mitosis and sheeting pattern is also observed in this study. 
Table No-13 
 
AGE WISE INCIDENCE OF MENINGIOMA 
 
S.No Grade 1-10 Yrs 
11-20 
Yrs 
21-30 
Yrs 
31-40 
Yrs 
41-50 
Yrs 
51-60 
Yrs 
61-70 
Yrs 
1.  I - - 2 6 4 1 1 
2.  II - - - - - - - 
3.  III - - - 1 - - - 
 
Table.13 shows grade. I meningiomas are common in the age group of 31 – 40 yrs 
followed by 41 – 50 yrs. No cases are seen in the age group of 1 – 20 yrs. 
 Following table No.14 shows that meningiomas are more common in females [9 
cases,60%] compared to males [ 6 cases, 40%].       
 
Table No-14 
 
SEX WISE INCIDENCE OF MENINGIOMA 
 
S.No Grade Male Female 
1.  I 5 9 
2.  II - - 
3.  III 1 - 
 Total 6 (40%) 9 (60%) 
 
Following table no.14 shows that meningiomas are more common in females 9 
cases 60% compared to males with 6 cases (40%). One case of anaplastic 
meningioma is seen in the male population. 
 
 Table No-15 
 
WHO GRADING OF NEURAL TUMORS [7/83 CASES] 
 
S.No Pathology Numbers HPE Diagnosis Site Mitosis Necrosis Grading
1. 1732/07 Neurofibroma Not Known - - I 
2. 2191/07 Schwannoma Cerebello Pontine Angle - - I 
3. 2776/07 Schwannoma Cerebello Pontine Angle - - I 
4. 167/08 Schwannoma Cerebello Pontine Angle - - I 
5. 1735/08 Ancient Schwannoma Not Known - - I 
6. 2552/08 Schwannoma Cerebello Pontine Angle - - I 
7. 2468/08 Schwannoma Cerebello Pontine Angle - - I 
 
Tumors of cranial and peripheral nerves span a wide range of histological features 
and associated clinical characteristics. More frequently they occur in the setting of 
familial cancer syndromes. The tumors under this group are schwannomas, 
neurofibromas, perineuromas [Grade-I] and Malignant peripheral nerve sheath 
tumors [WHO grade III to IV]. Grading done on the basic of mitosis and necrosis. 
Tumors seen in our study are graded as per the above norms.  
 
Table 15 illustrates that schwannoma is the common neural tumor seen in our 
study, 6 out of 7 cases with only one case of neurofibroma. The site is known in 5 
cases, being the cerebellopontine angle. Site is not known in 2 cases. All cases 
show no necrosis or increased mitotic activity. 
The below Table No.16 shows the age wise incidence of schwannoma commonly 
seen in the age of 31-40 yrs [3 cases] followed by 61-70 yrs [2 cases]  
Table-16 
 
AGE WISE INCIDENCE OF SCHWANNOMA 
 
S.No Pathology Numbers 1-10 Yrs 
11-20 
Yrs 
21-30 
Yrs 
31-40 
Yrs 
41-50 
Yrs 
51-60 
Yrs 
61-70 
Yrs 
1. 2191/07 - - - - - - 1 
2. 2776/07 - - - 1 - - - 
3. 167/08 - - - - 1 - - 
4. 1735/08 - - - 1 - - - 
5. 2252/08 - - - - - - 1 
6. 2468/08 - - - 1 - - - 
 
Table No-17 
SEX WISE INCIDENCE OF SCHWANNOMA 
 
S.No Pathology Numbers Male Female 
1.  2191/07 1 - 
2.  2776/07 - 1 
3.  167/08 1 - 
4.  1735/08 - 1 
5.  2252/08 - 1 
6.  2468/08 - 1 
 Total 2[33%] 4[66%] 
Table-17 exhibits the sex wise incidence of schwannoma. Our study shows a 
preponderance of females in the incidence of schwannomas [4 cases, 66%] 
compared to males who show an incidence of [2 cases, 33%]  
CNS tumors are the second commonest occurring neoplasm in the pediatric 
population, next to hematological malignancies Embryonal tumors are the 
commonest CNS neoplasms in children. In our study 11 cases are in the pediatric 
age group giving an incidence of 13.2% of all CNS neoplasms. The various CNS 
neoplasms seen in our study are exhibited  in table No:18. 
Table No-18 
 
INCIDENCE OF CNS NEOPLASMS IN PEDIATRIC POPULATION 
 
S.No Pathology Numbers HPE Diagnosis Grade 
1. 133/07 Medulloblastoma (Fig.14) IV 
2. 1485/07 Rhabdomyosarcoma/Lymphoma - 
3. 2613/07 Oligodendroglioma (Fig17) II 
4. 2665/07 Choroid Plexus Papilloma (Fig16) I 
5. 57/08 Craniopharyngioma (Fig15) I 
6. 237/08 Craniopharyngioma I 
7. 1768/08 Medulloblastoma IV 
8. 2314/08 Medulloblastoma IV 
9. 3148/08 Medulloblastoma IV 
10. 179/09 Astrocytoma II 
11. 458/09 Small Round Blue Cell Tumour - 
 
Table 18 (Fig39) shows that medulloblastoma is the commonest CNS neoplasm in 
pediatric population in our study [4 cases, 36%] followed by craniopharyngioma 
[2 cases-18%]. One case each of oligodendroglioma, choroid plexus papilloma and 
astrocytoma are seen. 2 doubtful cases diagnosed as Small Blue Round cell tumor 
and   Rhabdomyosarcoma / lymphoma are seen for which immunohistochemistry 
is done for confirmation.  
Table No-19 
SEX WISE INCIDENCE OF CNS NEOPLASM ACCORDING TO WHO 
GRADE IN PEDIATRIC POPULATION 
 
Grade Male Female 
I - 3 
II - 2 
III - - 
IV 2 2 
 
Table no 19 (Fig40) shows that pediatric  CNS neoplasms are commonly seen in 
female children 7 out of 11 cases [63.6%] compared to male who show an 
incidence of 2 cases [18.2%]. 
Metastatic tumors are neoplasms involving the CNS but are discontinuous 
with primary systemic neoplasms. Intracranial metastasis is most frequent in brain 
and dura. Origin of brain metastasis is mostly from respiratory tract, breast and 
skin. The metastatic tumors seen in our study with probable site of primary is 
illustrated in table no:20. 
Table No-20 
INCIDENCE OF METASTATIC TUMORS WITH PROBABLE 
SITE OF PRIMARY [5/83 CASES] 
S.No Pathology Numbers Age/Sex HPE Diagnosis 
Probable 
Site 
1. 2532/07 27/F  Choriocarcinoma (Fig18) Uterus 
2. 292/08 50/F Adenocarcinoma (Fig19) Breast 
3. 52/08 27/F Carcinoma (Fig20) Not Known 
4. 2469/08 45/F Follicular Carcinoma (Fig.21) Thyroid 
5. 2637/08 40/F Adenocarcinoma Not Known 
 
Table 20 shows that 5 cases of metastasis are seen in our study with an incidence 
of 6.03% All the cases are seen in females with site of primary known in 3 cases, 
sites being breast uterus and thyroid. The site is not known in 2 cases.    
Table 21 
Immunohistochemical analysis of CNS tumors [4 cases] 
Immunohistochemical analysis is done for 4 cases in our study where 
diagnosis based only on light microscopy was difficult. The results are 
illustrated in the below table.     
S.No Pathology Nos 
HPE 
Diagnosis GFAP Synaptophysin Desmin
CD 
40 CD68 
Final 
Diagnosis 
1.  2172/07 
Glioblastoma 
Multiforme 
small cell 
variant  
-ve +ve ND ND ND 
Primitive 
Neuroectoder
mal tumor 
(Fig24,25) 
2.  1485/07 
RMS/Lympho
ma/Malignant 
Histiocytosis 
ND ND -ve -ve +ve 
Malignant 
Histiocytosis 
(Fig26,27) 
3.  323./08 Gliosareoma / Lymphoma +ve ND ND -ve ND 
Gliosarcoma 
(Fig28,29,30)
4.  458/09 
Small round 
Blue cell 
Tumors 
-ve +ve ND ND ND 
Primitive 
Neuroectoder
mal tumor 
(Fig31,32) 
 
ND : Not done 
GFAP : Glial Fibrillary Acidic Protein 
 
Immunohistochemical analysis of 4 cases posing diagnostic problems is done with 
a panel of antibodies consisting of  GFAP, Synaptophysin, desmin, CD40 and CD 
68 . GFAP found positive in 1 case and a final diagnosis of  Gliosarcoma given.  
Synaptophysin  found positive in 2 cases and a diagnosis of Primitive 
Neuroectodermal tumor made in both. CD 68 found positive in 1 case where a 
panel of other 2 markers were also used (Desmin and CD 40), left with the 
diagnosis of Malignant Histiocytosis.  
 
 
 
CONCLUSION 
  
In the present prospective study of 83 central nervous system neoplasms 
evaluated with clinical, histopathological, histochemistry and 
immunohistochemistry, the following conclusions are made and presented. 
 
1. The incidence of CNS neoplasms is 9.97%. 
2. High incidence of CNS neoplasms is seen in the 3rd and 4th decade with 
slight female predominance. 
3. Primary CNS tumors are seen supratentorially in adults and in children it 
occurs infratentorially. 
4. Astrocytomas constitute the most common CNS tumor. 
5. Grading of astrocytomas by WHO norms reveal grade II pattern as the 
commonest. 
6. Meningiomas and Schwannomas constitute the next common CNS tumor. 
7. In the pediatric age group, grade IV neoplasms are common, 
medulloblastoma being the commonest malignant tumor. 
8. Metastatic tumors to the brain are commonly seen in females in the 2nd to 
4th decade, probable sites of primary being uterus, breast and thyroid. 
9. Special stains help in the diagnosis of CNS tumors to a limited extent. 
10. In doubtful cases immunohistochemical markers provide a valuable tool in 
arriving at a final diagnosis. 
 
  Immunohistochemistry is one of the most important tools of diagnostic 
histopathology. But now more stress is on finding tumor marker of prognostic 
significance. Survival in astrocytic gliomas is closely related to WHO tumor 
grade. Within tumor grade, especially in grade II and III tumors, the clinical 
course is variable and can hardly be predicted by histological criteria. 
Neovascularisation is a neuropathological hallmark in high grade gliomas and 
angiogenic factors may play an important role in malignant tumor progression. 
 
  Recently there has been conjecture that primary brain tumor incidence is 
increasing. This apparent rise is most likely caused by factors such as better 
diagnostic procedures and improved access to medical care. The future 
immunohistochemistry is aimed at not only the diagnosis and prognostication of 
the tumors but also being able to comment upon the probable response to various 
adjuvant agents. 
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WHO Classification of Tumors of the Nervous System  
Neurofibroma 
9540/0 Chondrosarcoma 9220/3 
  Osteoma 9180/0 
Plexiform 9550/0 Osteosarcoma 9180/3 
  Osteochondroma 9210/0 
Perineurioma 9540/0 Haemangioma 9120/0 
  Epithelioid haemangioendothelioma 9133/1 
Intraneural perineurioma 9571/0 Haemangiopericytoma 9150/1 
Soft tissue perineurioma 
9571/0 
Angiosarcoma 9120/3 
  Kaposi sarcoma 9140/3 
Malignant peripheral    
'Nerve sheath tumor (MPNST) 9540/3   
  Primary melanocyte lesions  
Epithelioid 9540/3 Diffuse melanocytosis 8728/0 
MPNST with divergent  Melanocytoma 8728/1 
Mesenchymal and / or epithelial  Malignant melanoma 8720/0 
differentiation 9540/3 Meningeal melanomatosis 8728/3 
Melanotic 9540/3   
Melanotic psammomatous 9540/3   
TUMORS OF THE MENINGES  Tumors of uncertain histogenesis Haemangioblastoma 9161/1
Tumors of meningothelial cells    
Meningioma 9530/0   
Meningothelial  9531/0 LYMPHOMAS AND HAEMOPOIETIC  
Fibrous (fibroblastic) 9532/0 NEOPLASMS  
Transitional (mixed) 9537/0   
Psammomatous 9533/0 Malignant lymphomas 9590/3
Angiomatous 9534/0 Plasmacytoma 9731/3
Microcystic 9530/0 Granulocytic sarcoma 9930/3
Secretory 9530/0  
Lymphoplasmacyte-rich 9530/0  
Metaplastic 9530/0 GERM CELL TUMORS 
Clear cell 9538/1 Germinoma 9064/3
Chordoid 9538/1 Embryonal carcinoma 9070/3
Atypical 9539/1 Yolk sac tumors 9071/3
Papillary 9538/3 Choriocarcinoma 9100/3
Rhabdoid 9538/3 Teratoma 9080/1
Anaplastic meningioma 9530/3 Mature 9080/0
Mesenchymal, non-meningothelial tumors  Immature 9080/3
Lipoma         8850/0 Teratoma with malignant 
Angiolipoma 8861/0 Transformation 9084/3
Hibernoma 8880/0 Mixed germ cell tumors 9085/3
Liposarcoma (intracranial) 8850/3  
Solitary fibrous tumors 8815/0  
Fibrosarcoma 8810/3  
Malignant fibrous histiocytoma 8830/3 TUMORS OF THE SELLAR REGION 
Leiomyoma 8890/0 Craniopharyngioma ' 9350/1
Leiomyosarcoma 8890/3 Adamantinomatous 9351/1
Rhabdomyoma 8900/0 Papillary 9352/1
Rhabdomyosarcoma 8900/3 Granular cell tumor 9582/0
Chondroma 9220/0   
Adopted from World Health Organization classification of tumors pathology & genetic tumors of the nervous system 2000 edited by Paul kleihues & Webster K. Cavenee 
WHO Classification of Tumors of the Nervous System 
 
Tumors of Neuroepithelial Tissue  
 
Astrocytic tumors 
Diffuse astrocytoma 9400/3 
Fibrillary astrocytoma 9420/3 
Protoplasmic astrocytoma 9410/3 
Gemistocytic astrocytoma 9411/3 
Anaplastic astrocytoma 9401/3 
Glioblastoma 9440/3 
Giant cell glioblastoma 9411/3 
Gliosarcoma 9442/3 
Pilocytic astrocytoma 9421/1 
Pleomorphic xanthoastrocytoma 9424/3 
Subependymal giant cell Astrocytoma 9384/1 
 
Oligodendroglial tumors 
Oligodendroglioma 9450/3 
Anaplastic Oligodendroglioma 9451/3 
 
Mixed gliomas 
 
Oligoastrocytoma 9382/3 
.Anaplastic oligoastrocytoma 9382/3 
 
Ependymal tumors 
 
Ependymoma 9391/3 
Cellular 9391/3 
Papillary 9393/3 
Clear cell 9391/3 
Tanycytic 9391/3 
Anaplastic ependymoma 9392/3 
Myxopapillary ependymoma  9394/1 
Subependymoma         9383/1 
 
Choroid plexus tumors 
Choroid plexus papilloma 9390/0 
Choroidplexus carcinoma 9390/3 
 
Glial tumors of uncertain origin 
Astroblastoma       9430/3 
Gliomatosis cerebri   9381/3 
Chordoid glioma of the3rd ventricle      
9444/1 
 
Neuronal and mixed neuronal-Glial 
tumors 
Gangliocytoma    9492/ 
Dysplastic gangliocytoma of  
cerebellum(Lhermitte-Duclos)                9493/    
9493/Desmoplastic infantile 
Astrocytoma / ganglioglioma     9412/ 
Dysembryoplastic neuroepithelial tumor 9413/ 
Ganglioglioma     9505/ 
Anaplastic ganglioglioma     9505/ 
Central neurocytoma     9506/ 
Cerebellar liponeurocytoma     9506/ 
Paraganglioma of the filum terminale     8680/ 
 
Neuroblastic tumors 
 
Olfactory neuroblastoma 
(Aesthesioneuroblastoma)      9522/ 
Olfactory neuroepithelioma      9523/ 
Neuroblastomas of the adrenal gland 
and sympathetic nervous system       9500/ 
 
Pineal parenchymal tumors  
 
Pineocytoma      9361/ 
Pineoblastoma      9362/ 
Pineal parenchymal tumor of 
Intermediate differentiation      9362/ 
 
Embryonal tumors 
Medulloepithelioma      9501/ 
Ependymoblastoma      9392/ 
Medulloblastoma                                      9470/ 
Desmoplastic medulloblastoma    9471/ 
Large cell medulloblastoma     9474/ 
Medullomyoblastoma     9472/ 
Melanotic medulloblastoma      9470/ 
Supratentorial primitive 
Neuroectodermal tumor (PNET)      9473/ 
Neuroblastoma     9500/ 
Ganglioneuroblastoma     9490/ 
Atypical teratoid / Rhabdoidal tumor      9508/ 
 
Tumors of Peripheral Nerves  
Schwannoma 
(Neurilemmoma, Neurinoma)    9560/0 
Cellular   9560/0 
Plexiform   9560/0 
Melanotic   0560/0 
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